Published in Antimicrob Agents Chemother on February 22, 2010
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother (2013) 1.63
Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother (2011) 1.15
Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother (2010) 1.11
Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob Agents Chemother (2010) 0.97
Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother (2013) 0.87
Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother (2011) 0.87
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol (2015) 0.85
Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrob Agents Chemother (2013) 0.85
Rapid and sensitive liquid chromatography/mass spectrometry assay for caspofungin in human aqueous humor. Antimicrob Agents Chemother (2010) 0.78
High Intracellular Concentrations of Posaconazole Do Not Impact on Functional Capacities of Human Polymorphonuclear Neutrophils and Monocyte-Derived Macrophages In Vitro. Antimicrob Agents Chemother (2016) 0.76
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis (2008) 5.39
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother (2003) 3.03
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos (2003) 2.91
Adverse reactions to voriconazole. Clin Infect Dis (2004) 2.51
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother (2006) 2.31
Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother (2006) 2.00
Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit (2008) 1.93
Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol (2006) 1.88
Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother (2006) 1.75
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer (2007) 1.65
Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly (2006) 1.61
Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother (2006) 1.53
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob Agents Chemother (2008) 1.35
Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol Pharm Bull (2004) 1.30
Hallucinations during voriconazole therapy. Clin Infect Dis (2008) 1.28
Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis (2008) 1.27
Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet (1998) 1.12
Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 1.10
Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol (2005) 1.10
Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses (1999) 1.06
Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol (2007) 1.06
Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes. Antimicrob Agents Chemother (1993) 0.97
Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. J Antimicrob Chemother (2005) 0.91
Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages. J Med Microbiol (2006) 0.90
Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high-performance liquid chromatography with ion spray and turbo ion spray tandem mass spectrometric detection. J Chromatogr B Biomed Sci Appl (1999) 0.87
Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samples. J Mass Spectrom (2007) 0.85
An advanced double column-switching technique (LC-LC) for liquid chromatography/electrospray ionisation tandem mass spectrometry for fully automated analysis of caspofungin. Rapid Commun Mass Spectrom (2004) 0.84
Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrob Agents Chemother (2008) 0.84
Synergy of itraconazole with macrophages in killing Blastomyces dermatitidis. Antimicrob Agents Chemother (1992) 0.84
Fast, fully automated analysis of voriconazole from serum by LC-LC-ESI-MS-MS with parallel column-switching technique. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.81
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood (2005) 2.97
Continuous infusion of clonidine in ventilated newborns and infants: a randomized controlled trial. Pediatr Crit Care Med (2014) 2.69
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs (2007) 2.09
Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood (2013) 2.09
Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica (2010) 1.91
Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy (2008) 1.79
Patients at high risk of invasive fungal infections: when and how to treat. Drugs (2008) 1.62
Central venous catheter (CVC)-related infections in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2003) 1.62
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis (2006) 1.54
Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question? Leuk Lymphoma (2010) 1.40
Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis (2012) 1.39
Growth independent rhamnolipid production from glucose using the non-pathogenic Pseudomonas putida KT2440. Microb Cell Fact (2011) 1.31
Insights into the function of the WhiB-like protein of mycobacteriophage TM4--a transcriptional inhibitor of WhiB2. Mol Microbiol (2010) 1.30
Walking ability during daily life in patients with osteoarthritis of the knee or the hip and lumbar spinal stenosis: a cross sectional study. BMC Musculoskelet Disord (2010) 1.26
The baffled microtiter plate: increased oxygen transfer and improved online monitoring in small scale fermentations. Biotechnol Bioeng (2009) 1.23
Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend (2005) 1.21
Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2008) 1.17
Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients. J Acquir Immune Defic Syndr (2008) 1.15
Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. Infect Control Hosp Epidemiol (2003) 1.15
Robo-Lector - a novel platform for automated high-throughput cultivations in microtiter plates with high information content. Microb Cell Fact (2009) 1.15
Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol (2012) 1.15
Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients. PLoS One (2010) 1.15
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer (2009) 1.13
Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos (2008) 1.12
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol (2012) 1.11
Physical activity and childhood cancer. Pediatr Blood Cancer (2010) 1.08
Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology (2012) 1.08
Recent developments in the management of invasive fungal infections in patients with hematological malignancies. Ann Hematol (2004) 1.08
Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy (2011) 1.07
HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses (2006) 1.06
Posaconazole concentrations in the central nervous system. J Antimicrob Chemother (2008) 1.06
Invasive candidiasis and candidemia: from current opinions to future perspectives. Expert Opin Investig Drugs (2009) 1.03
Fungal endocarditis. Curr Opin Infect Dis (2013) 1.00
Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. Int J Antimicrob Agents (2009) 0.98
Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob Agents Chemother (2010) 0.97
A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect (2007) 0.97
Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2013) 0.96
Microfluidic biolector-microfluidic bioprocess control in microtiter plates. Biotechnol Bioeng (2010) 0.96
PTX3 deficiency and aspergillosis. N Engl J Med (2014) 0.96
Our 2014 approach to mucormycosis. Mycoses (2014) 0.96
Mycobacterial phenolic glycolipid inhibits phagosome maturation and subverts the pro-inflammatory cytokine response. Traffic (2008) 0.95
MHC class I chain-related protein A shedding in chronic HIV-1 infection is associated with profound NK cell dysfunction. Virology (2010) 0.94
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica (2013) 0.93
Posaconazole: a next-generation triazole antifungal. Future Microbiol (2007) 0.93
Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction. Clin Chem Lab Med (2008) 0.93
Level of activity in children undergoing cancer treatment. Pediatr Blood Cancer (2009) 0.93
Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis (2008) 0.92
Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother (2011) 0.91
Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol (2013) 0.90
A designed TLR4/MD-2 complex to capture LPS. J Endotoxin Res (2005) 0.89
Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother (2010) 0.89
Identification of three cytotoxic early proteins of mycobacteriophage L5 leading to growth inhibition in Mycobacterium smegmatis. Microbiology (2008) 0.89
Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int J Antimicrob Agents (2006) 0.89
Bioprocess control in microscale: scalable fermentations in disposable and user-friendly microfluidic systems. Microb Cell Fact (2010) 0.89
Increased product formation induced by a directed secondary substrate limitation in a batch Hansenula polymorpha culture. Appl Microbiol Biotechnol (2009) 0.89
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother (2009) 0.88
[Lymph node tuberculosis as primary manifestation of Hodgkin's disease]. Med Klin (Munich) (2006) 0.87
Aspergillus PCR testing: results from a prospective PCR study within the AmBiLoad trial. Eur J Haematol (2010) 0.87
VPA response in SMA is suppressed by the fatty acid translocase CD36. Hum Mol Genet (2012) 0.87
Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol (2008) 0.87
Bacterial translocation increases phagocytic activity of polymorphonuclear leucocytes in portal hypertension: priming independent of liver cirrhosis. Liver Int (2008) 0.87
Longitudinal analysis of distribution and function of plasmacytoid dendritic cells in peripheral blood and gut mucosa of HIV infected patients. J Infect Dis (2013) 0.86
Asymmetric division of Hansenula polymorpha reflected by a drop of light scatter intensity measured in batch microtiter plate cultivations at phosphate limitation. Biotechnol Bioeng (2009) 0.86
Lung and heart-lung transplantation in children and adolescents: a long-term single-center experience. J Heart Lung Transplant (2009) 0.86
Diagnosis and treatment of documented infections in neutropenic patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2003) 0.86
Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol (2012) 0.85
Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. Br J Haematol (2014) 0.85
Antifungal treatment strategies in high risk patients. Mycoses (2008) 0.85
Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice. Future Microbiol (2006) 0.85
Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrob Agents Chemother (2013) 0.85
Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health (2006) 0.84
Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol (2007) 0.84
OAT2 catalyses efflux of glutamate and uptake of orotic acid. Biochem J (2011) 0.83
Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis (2012) 0.83
Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses (2011) 0.83
Anidulafungin--state of affairs from a clinical perspective. Mycoses (2007) 0.82
Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry. Clin Chem Lab Med (2015) 0.82